Prosecution Insights
Last updated: April 19, 2026
Application No. 18/041,582

PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND

Final Rejection §102§112
Filed
Feb 14, 2023
Examiner
BAKSHI, PANCHAM
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kyushu University National University Corporation
OA Round
2 (Final)
77%
Grant Probability
Favorable
3-4
OA Rounds
2y 5m
To Grant
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allow Rate
873 granted / 1132 resolved
+17.1% vs TC avg
Strong +30% interview lift
Without
With
+30.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
77 currently pending
Career history
1209
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
32.0%
-8.0% vs TC avg
§102
23.0%
-17.0% vs TC avg
§112
27.0%
-13.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1132 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application Claims 1-11 and 13-16 are pending, of which Claims 4, 8-10, 15 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 1-3, 5-7, 11, 13-14 and 16 are under current examination. Amendment necessitated new claim rejection as set forth below. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-3, 5-7, 11, 13-14 and 16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 1 is indefinite as claim 1 recites “and having a naphthalene ---any other ring”. It is unclear if the recited limitation is for naphthalene compound or it’s another substituent on naphthalene compound. If applicant intends the limitation for the naphthalene compound, applicant is suggested to recite “wherein the naphthalene compound has a naphthalene skeleton that is ----not condensed with any other ring”. Since the dependent claims doesn’t cure the above deficiency, claims 2 -3, 5-7, 11, 13-14 and 16 are also indefinite. Appropriate correction required. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-3, 5-7, and 13 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Nishimura (ACS Materials Lett., 2019, 1, 660-664). Nishimura discloses a method of photon upconversion comprising irradiating a composition containing a 1, 4-disubstitued naphthalene compound substituted with two alkynyl groups substituted with silyl group (same group as in the elected species) in 1, 4-position and a benzene ring (i.e., 3 substituents), with a visible light (380-740nm): PNG media_image1.png 871 608 media_image1.png Greyscale PNG media_image2.png 514 844 media_image2.png Greyscale (entire article). The naphthalene compound substituted with two alkynyl groups substituted with silyl group (same group as in the elected species) in 1, 4-position and a benzene ring (i.e., 3 substituents) reads on compound of the instant claim 7, when m=2, n=1, R1=R2=R3=isopropyl; X=aromatic ring. Since the cited prior art reads on all the limitations of the instant claims 1-3, 5-7, and 13, these claims are anticipated. Claims 1-3, 5-7, 11, 13-14 and 16 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Maeda (Journal of Photochemistry and Photobiology A: Chemistry 342 (2017)153-160). Maeda discloses synthesis and luminescence properties of 1, 4-bis(silylethynyl)naphthalenes) compounds: PNG media_image3.png 412 567 media_image3.png Greyscale and composition comprising such compounds (compounds 1a-2c reads on the instant claims) in the form of film when irradiated with a light, with UV and visible light (entire article). With regard to the limitation of the instant claims, “photon upconversion”, since the cited prior art teaches same method using same compound, the process of the cited prior art must be capable of being able to accomplish “photon upconversion”. Importantly, “photon upconversion”, is an inherent property of a compound when irradiated and the compound of the cited prior art is expected to accomplish “photon upconversion”, when irradiated with light. Further, if the body of a claim fully and intrinsically sets forth all of the limitations of the claimed invention, and the preamble merely states, for example, the purpose or intended use of the invention, rather than any distinct definition of any of the claimed invention’s limitations, then the preamble is not considered a limitation and is of no significance to claim construction. Pitney Bowes, Inc. v. Hewlett-Packard Co., 182 F.3d 1298, 1305, 51 USPQ2d 1161, 1165 (Fed. Cir. 1999). See also Rowe v. Dror, 112 F.3d 473, 478, 42 USPQ2d 1550, 1553 (Fed. Cir. 1997) (“where a patentee defines a structurally complete invention in the claim body and uses the preamble only to state a purpose or intended use for the invention, the preamble is not a claim limitation”); Kropa v. Robie, 187 F.2d at 152, 88 USPQ2d at 480-81 (preamble is not a limitation where claim is directed to a product and the preamble merely recites a property inherent in an old product defined by the remainder of the claim); STX LLC. v. Brine, 211 F.3d 588, 591, 54 USPQ2d 1347, 1350 (Fed. Cir. 2000). Thus, the cited prior art reads on all limitations of the instant claims. Since the cited prior art reads on all the limitations of the instant claims 1-3, 5-7, 11, 13-14 and 16, these claims are anticipated. Claims 1, 3, 5-6, 11, 13-14 and 16 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Xia (US8742657 B2). Xia discloses a method of photon upconversion comprising irradiating a composition and/or a film containing such composition, containing a 1, 4-disubstitued naphthalene compound substituted with two alkynyl groups substituted in 1, 4-position, halogen and a benzene ring (i.e., 4 substituents), with a visible light (absorption), such as 500nm to 600nm and emission with a wavelength of about 400nm (UV) (i.e., conversion of visible to UV) (entire patent, especially abstract, col 3, 4, 7, 8, 13-14, Table 1, 25-30, 33, 49, 50, 57, 58, 91-94, 97, 98 and claims) PNG media_image4.png 307 738 media_image4.png Greyscale Or compound (wherein the naphthalene compound has a naphthalene skeleton that is ----not condensed with any other ring) PNG media_image5.png 254 337 media_image5.png Greyscale Or PNG media_image6.png 445 1120 media_image6.png Greyscale Since the cited prior art reads on all the limitations of the instant claims 1, 3, 5-6, 11, 13-14 and 16, these claims are anticipated. Response to Arguments Applicant’s remarks and amendment, filed on 01/02/2026, have been fully considered but not found persuasive. Applicant’s argument is moot in view of new rejection as set forth above. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Conclusion No Claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PANCHAM BAKSHI whose telephone number is (571)270-3463. The examiner can normally be reached M-Thu 7-4.30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Milligan Adam can be reached at 571-2707674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PANCHAM BAKSHI/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Feb 14, 2023
Application Filed
Sep 23, 2025
Non-Final Rejection — §102, §112
Jan 02, 2026
Response Filed
Mar 10, 2026
Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595353
PLASTICIZER COMPOSITION AND RESIN COMPOSITION COMPRISING THE SAME
2y 5m to grant Granted Apr 07, 2026
Patent 12594293
USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
2y 5m to grant Granted Apr 07, 2026
Patent 12590162
CANCER TREATMENT
2y 5m to grant Granted Mar 31, 2026
Patent 12565514
NUCLEIC ACID CONTAINING PERFLUOROALKYL GROUP, AND METHOD FOR ITS PRODUCTION
2y 5m to grant Granted Mar 03, 2026
Patent 12565466
SYNTHESIS AND USE OF PRECURSORS FOR VAPOR DEPOSITION OF TUNGSTEN CONTAINING THIN FILMS
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+30.4%)
2y 5m
Median Time to Grant
Moderate
PTA Risk
Based on 1132 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month